Omicron News and Research

RSS

Study shows consistent efficacy of Paxlovid regardless of age, number of vaccinations, comorbidities

In a recent study posted to the medRxiv* preprint server, researchers in Canada evaluated nirmatrelvir and ritonavir (Paxlovid) effectiveness against severe coronavirus disease 2019 (COVID-19) during the dominance of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant of concern (VOC) and Omicron sub-VOCs in Canada.

7 Nov 2022

Evaluating dual direct-acting antivirals against persistent COVID-19

Researchers assessed the efficiency of dual direct-acting antivirals in treating persistent coronavirus disease 2019 (COVID-19).

7 Nov 2022

The Native Antigen Company expands its range of Omicron antigens to include BA.5 variant

The Native Antigen Company (part of LGC Clinical Diagnostics), one of the world’s leading suppliers of reagents that enables research into vaccines and diagnostics for emerging and endemic infectious diseases, today announced the commercial launch of its latest SARS-CoV-2 antigens for the newly designated Omicron BA.5 variant.

From The Native Antigen Company 7 Nov 2022

Does the time of day patients receive their COVID-19 vaccinations influence their clinical benefit?

Researchers investigated whether the time of day at which COVID-19 patients receive their SARS-CoV-2 vaccinations influences the vaccine effectiveness.

7 Nov 2022

Study shows likely SARS-CoV-2 transmission between different rooms of a quarantine hotel

The results of this study, published in the Emerging Infectious Diseases journal, underline the enhanced transmissibility of the Omicron variants of the virus, which takes advantage of small airstreams to jump to new hosts. "Our findings emphasize the importance of ventilation and integrity of building structure in quarantine facilities."

6 Nov 2022

Influenza hospitalizations at highest level in ten years, predicting a severe U.S. flu season

Influenza infection and hospitalization rates continue to increase at an alarmingly fast and early rate this year.

6 Nov 2022

Moderna's COVID-19 vaccine safe and effective in children 6 months to 5 years of age

Moderna's COVID-19 vaccine is safe and effective in children 6 months to 5 years of age, a clinical trial co-led by Vanderbilt University Medical Center vaccine expert C. Buddy Creech, MD, MPH, has found.

4 Nov 2022

Exploring BNT162b2 vaccine effectiveness against COVID-19 among pediatric and adolescent population of Qatar

Researchers evaluated Pfizer-BioNTech’s BNT162b2 messenger ribonucleic acid (mRNA) vaccine effectiveness (VE) against SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infections among the pediatric and adolescent population of Qatar.

4 Nov 2022

SARS-CoV-2 Omicron's newest subvariant BQ.1.1 shows extraordinary immune evasion potential against vaccine sera

In a new study, researchers pursued immunological evidence of why BQ.1.1 prevalence swiftly increased in areas where Omicron BA.5 was dominant in the United States (US).

4 Nov 2022

What were the SARS-CoV-2 seroprevalence estimates for industrial livestock operation workers in the USA for 2021-2022?

In a new study, researchers measured SARS-CoV-2 seroprevalence in industrial livestock operation workers of North Carolina, United States, between February 2021 and July 2022.

4 Nov 2022

Persistent COVID-19 symptoms among South Africans infected during SARS-CoV-2 Beta, Delta and Omicron variant waves

Researchers longitudinally followed up hospitalized (H) and non-hospitalized (NH) COVID-19 patients for six months after laboratory-confirmed SARS-CoV-2 infections to identify factors that increase the risk of post-COVID-19 condition development in the South African population.

4 Nov 2022

Efficacy of booster messenger ribonucleic acid COVID-19 vaccinations against SARS-CoV-2 Omicron variant severity

Researchers estimated the effectiveness of monovalent messenger ribonucleic acid (mRNA) coronavirus disease 2019 (COVID-19) vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant of concern (VOC) infection severity outcomes among adults.

4 Nov 2022

Study evaluates BA.5-bivalent booster against new Omicron sublineages

In a new study, researchers evaluated the efficacy of four doses of parental messenger ribonucleic acid (mRNA) vaccine and a BA.5-bivalent booster against recently emerged Omicron sublineages. Additionally, they determined whether prior infection improved the effect of a booster vaccination.

4 Nov 2022

Specific mutations in the monkeypox virus contribute to its continued infectiousness

Monkeypox has infected more than 77,000 people in more than 100 countries worldwide, and - similar to COVID-19 - mutations have enabled the virus to grow stronger and smarter, evading antiviral drugs and vaccines in its mission to infect more people.

4 Nov 2022

Novel monoclonal antibodies NA8 and NE12 can neutralize most SARS-CoV-2 variants and Omicron subvariants

Researchers generated and characterized two monoclonal antibodies (NA8 and NE12) that target the receptor binding domain of the SARS-CoV-2 spike protein, and exhibit neutralizing activity against major SARS-CoV-2 variants of concern.

3 Nov 2022

Ventilation rates need to increase substantially to bring down Omicron infection probability

With SARS-CoV-2 variants continuing to evolve, building scientists and air quality specialists have assessed the ventilation rates of rooms required to keep the risk of infection under one percent, concluding that Omicron and its sublineages require ventilation some 50 times greater than the virus did when humanity first encountered it in the spring of 2020.

3 Nov 2022

Scientists identify a cryptic SARS-CoV-2 lineage in wastewater

In a recent study posted to the medRxiv* preprint server, researchers in the United States investigated the source of an enigmatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant of concern (VOC)-like spike (S) protein strain detected in wastewater but not in clinical samples.

2 Nov 2022

Omicron News and Research

Study shows consistent efficacy of Paxlovid regardless of age, number of vaccinations, comorbidities

Evaluating dual direct-acting antivirals against persistent COVID-19

The Native Antigen Company expands its range of Omicron antigens to include BA.5 variant

Does the time of day patients receive their COVID-19 vaccinations influence their clinical benefit?

Study shows likely SARS-CoV-2 transmission between different rooms of a quarantine hotel

Influenza hospitalizations at highest level in ten years, predicting a severe U.S. flu season

Moderna's COVID-19 vaccine safe and effective in children 6 months to 5 years of age

Exploring BNT162b2 vaccine effectiveness against COVID-19 among pediatric and adolescent population of Qatar

SARS-CoV-2 Omicron's newest subvariant BQ.1.1 shows extraordinary immune evasion potential against vaccine sera

What were the SARS-CoV-2 seroprevalence estimates for industrial livestock operation workers in the USA for 2021-2022?

Persistent COVID-19 symptoms among South Africans infected during SARS-CoV-2 Beta, Delta and Omicron variant waves

Efficacy of booster messenger ribonucleic acid COVID-19 vaccinations against SARS-CoV-2 Omicron variant severity

Study evaluates BA.5-bivalent booster against new Omicron sublineages

Specific mutations in the monkeypox virus contribute to its continued infectiousness

Novel monoclonal antibodies NA8 and NE12 can neutralize most SARS-CoV-2 variants and Omicron subvariants

Ventilation rates need to increase substantially to bring down Omicron infection probability

Scientists identify a cryptic SARS-CoV-2 lineage in wastewater

Vimentin is an important co-receptor for SARS-CoV-2 infection

Bivalent mRNA booster broadens humoral immunity against SARS-CoV-2 Omicron subvariants

Scientists identify a broadly neutralizing antibody against all dominant SARS-CoV-2 variants

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News